Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Norsworthy KJ"'
Autor:
Hunter AM; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA., Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Itzykson R; Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, Centre National de la Recherche Scientifique, Paris, France.; Département Hématologie et Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France., Mesa R; Hematology and Medical Oncology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC., Karanes C; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Li Y; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., de Claro RA; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Norsworthy KJ; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Theoret M; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD., Pulte E; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Padron E; Hematologic Malignancies. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Publikováno v:
Blood [Blood] 2024 Nov 07; Vol. 144 (19), pp. 1987-1992.
Autor:
Woods AC; United States Food and Drug Administration, Silver Spring, Maryland, United States., Norsworthy KJ; United States Food and Drug Administration, Silver Spring, MD, United States., Choe M; United States Food and Drug Administration, Silver Spring, Maryland, United States., Gehrke BJ; Food and Drug Administration, White Oak, MD, United States., Chen H; United States Food and Drug Administration, Silver Spring, Maryland, United States., Vallejo J; United States Food and Drug Administration, Silver Spring, MD, United States., Pan L; United States Food and Drug Administration, Silver Spring, Maryland, United States., Jiang X; United States Food and Drug Administration, Silver Spring, Maryland, United States., Li H; United States Food and Drug Administration, Silver Spring, Maryland, United States., Kraft J; United States Food and Drug Administration, United States., Liu J; United States Food and Drug Administration, United States., Charlab R; United States Food and Drug Administration, Silver Spring, MD, United States., Okusanya OO; United States Food and Drug Administration, Silver Spring, MD, United States., Booth B; Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Md, United States., Pazdur R; United States Food and Drug Administration, Silver Spring, MD, United States., Theoret MR; Food and Drug Administration, Silver Spring, MD, United States., de Claro RA; United States Food and Drug Administration, Silver Spring, MD, United States.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 30. Date of Electronic Publication: 2024 Oct 30.
Autor:
Cortes JE; Georgia Cancer Center at Augusta University, Augusta, Georgia., Abruzzese E; Hematology, S. Eugenio Hospital, Tor Vergata University, Rome, Italy., Cardonick EH; Cooper Medical School of Rowan University, Camden, New Jersey., Hernández-Díaz S; Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Gutierrez J; Patient advocate, Castle Pines, Colorado., Sardegna MS; Patient advocate, Laguna Hills, California., Torres-Chavez E; Patient advocate, Riverside, California., Dinatale M; FDA, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Silver Spring, Maryland., Lerro CC; FDA, Oncology Center of Excellence, Silver Spring, Maryland., Gehrke BJ; FDA, Center for Drug Evaluation and Research, Office of Oncologic Diseases, Silver Spring, Maryland., Shord SS; FDA, Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Silver Spring, Maryland., De Claro RA; FDA, Center for Drug Evaluation and Research, Office of Oncologic Diseases, Silver Spring, Maryland., Theoret MR; FDA, Oncology Center of Excellence, Silver Spring, Maryland., DeMaria PJ; FDA, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Silver Spring, Maryland., Norsworthy KJ; FDA, Center for Drug Evaluation and Research, Office of Oncologic Diseases, Silver Spring, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3658-3666.
Autor:
Norsworthy KJ; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. kelly.norsworthy@fda.hhs.gov., Lee-Alonzo RJ; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA., Pazdur R; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
Publikováno v:
Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2024 May; Vol. 21 (5), pp. 333-334.
Autor:
Woods A; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Norsworthy KJ; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Wang X; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Vallejo J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Chiu Yuen Chow E; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Li RJ; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Sun J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Charlab R; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Jiang X; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Pazdur R; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., Theoret MR; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., de Claro RA; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 01; Vol. 30 (7), pp. 1226-1231.
Autor:
Sweet KL; Moffitt Cancer Center, Tampa, Florida., Cortes JE; Georgia Cancer Center, Augusta University, Augusta, Georgia., Apperley JF; Centre for Haematology, Imperial College, London, United Kingdom., Mann M; Patient Advocate, Jonesboro, Georgia., Mauro MJ; Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York City, New York., Oehler VG; Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington., Ruiz C; Patient Advocate, Jonesboro, Georgia., Schiffer CA; Department of Hematology-Oncology, Karmanos Cancer Center at Wayne State University, Detroit, Michigan., Ehrlich LA; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., Pamuk GE; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., Wynne J; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., Mehta GU; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., Okusanya OO; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., de Claro RA; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., Theoret MR; Oncology Center of Excellence, FDA, Washington, District of Columbia., Smith BD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland., Norsworthy KJ; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jan 05; Vol. 30 (1), pp. 237-238.
Autor:
Woods AC; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA., Norsworthy KJ; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
Publikováno v:
Cancers [Cancers (Basel)] 2023 Sep 28; Vol. 15 (19). Date of Electronic Publication: 2023 Sep 28.
Autor:
Sekeres MA; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida., Kim N; NCI, NIH, Bethesda, Maryland., DeZern AE; Johns Hopkins University, Baltimore, Maryland., Norsworthy KJ; Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland., Garcia JS; Dana-Farber Cancer Institute, Boston, Massachusetts., de Claro RA; Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland., Theoret MR; Oncology Center of Excellence, FDA, Silver Spring, Maryland., Jen EY; Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland., Ehrlich LA; Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland., Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, and Yale Cancer Center, Yale University, New Haven, Connecticut., Komrokji RS; H. Lee Moffitt Cancer Center, Tampa, Florida.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Jul 14; Vol. 29 (14), pp. 2573-2579.
Autor:
Sweet KL; Moffitt Cancer Center, Tampa, Florida., Cortes JE; Georgia Cancer Center, Augusta University, Augusta, Georgia., Apperley JF; Centre for Haematology, Imperial College, London, United Kingdom., Mann M; Patient Advocate, Jonesboro, Georgia., Mauro MJ; Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York City, New York., Oehler VG; Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington., Ruiz C; Patient Advocate, Los Angeles, California., Schiffer CA; Department of Hematology-Oncology, Karmanos Cancer Center at Wayne State University, Detroit, Michigan., Ehrlich LA; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC., Pamuk GE; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC., Wynne J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC., Mehta GU; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC., de Claro RA; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC., Theoret MR; Oncology Center of Excellence, U.S. Food and Drug Administration, Washington, DC., Smith BD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland., Norsworthy KJ; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Jun 13; Vol. 29 (12), pp. 2179-2183.
Autor:
Pulte D; Division of Hematologic Malignancies I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD. Electronic address: Elizabeth.pulte@fda.hhs.gov., Fernandes L; Division of Biometrics IX, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Wei G; Division of Biometrics IX, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Woods A; Division of Hematologic Malignancies I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Norsworthy KJ; Division of Hematologic Malignancies I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Gormley N; Division of Hematologic Malignancies II, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Kanapuru B; Division of Hematologic Malignancies II, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Gwise TE; Division of Biometrics IX, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Pazdur R; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD., Schneider J; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD., Theoret MR; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD., Fashoyin-Aje LA; Division of Oncology III, Center for Drug Evaluation and Research, and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD., de Claro RA; Division of Hematologic Malignancies I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.
Publikováno v:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Jun; Vol. 23 (6), pp. 463-470.e1. Date of Electronic Publication: 2023 Mar 30.